- Home
- CSQ vs SUPN Comparison
CSQ vs SUPN Comparison
Compare CSQ & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSQ
- SUPN
- Stock Information
- Founded
- CSQ 2003
- SUPN 2005
- Country
- CSQ United States
- SUPN United States
- Employees
- CSQ N/A
- SUPN N/A
- Industry
- CSQ Finance Companies
- SUPN Biotechnology: Pharmaceutical Preparations
- Sector
- CSQ Finance
- SUPN Health Care
- Exchange
- CSQ Nasdaq
- SUPN Nasdaq
- Market Cap
- CSQ 3.1B
- SUPN 2.6B
- IPO Year
- CSQ N/A
- SUPN 2012
- Fundamental
- Price
- CSQ $19.11
- SUPN $44.80
- Analyst Decision
- CSQ
- SUPN Buy
- Analyst Count
- CSQ 0
- SUPN 2
- Target Price
- CSQ N/A
- SUPN $43.00
- AVG Volume (30 Days)
- CSQ 220.3K
- SUPN 654.2K
- Earning Date
- CSQ 01-01-0001
- SUPN 11-03-2025
- Dividend Yield
- CSQ 7.53%
- SUPN N/A
- EPS Growth
- CSQ N/A
- SUPN 1411.53
- EPS
- CSQ N/A
- SUPN 1.14
- Revenue
- CSQ N/A
- SUPN $665,125,000.00
- Revenue This Year
- CSQ N/A
- SUPN $4.84
- Revenue Next Year
- CSQ N/A
- SUPN $17.69
- P/E Ratio
- CSQ N/A
- SUPN $38.93
- Revenue Growth
- CSQ N/A
- SUPN 5.55
- 52 Week Low
- CSQ $12.50
- SUPN $29.16
- 52 Week High
- CSQ $16.45
- SUPN $46.79
- Technical
- Relative Strength Index (RSI)
- CSQ 68.75
- SUPN 58.16
- Support Level
- CSQ $18.30
- SUPN $43.44
- Resistance Level
- CSQ $18.80
- SUPN $46.72
- Average True Range (ATR)
- CSQ 0.15
- SUPN 1.08
- MACD
- CSQ 0.04
- SUPN -0.48
- Stochastic Oscillator
- CSQ 89.50
- SUPN 40.60
About CSQ Calamos Strategic Total Return
Calamos Strategic Total Return Fund is a diversified, closed-end management investment company. The fund's objective is to provide total return through a combination of capital appreciation and current income. Its investment portfolio comprises equities, convertible securities, and high-yield corporate bonds.
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.